Clinical Gastroenterology and Hepatology最新文献

{"title":"Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B","authors":"Maria Kalafateli ,&nbsp;Roberta Forlano ,&nbsp;Eleanor Barnes ,&nbsp;Laura Martinez-Gili ,&nbsp;Madeleine Lacey ,&nbsp;Giordano Sigon ,&nbsp;Benjamin H. Mullish ,&nbsp;Vincent Mallet ,&nbsp;Lucia Parlati ,&nbsp;Paul Richardson ,&nbsp;Niamh Forde ,&nbsp;Gaetano Serviddio ,&nbsp;Rosanna Villani ,&nbsp;Sabela Lens ,&nbsp;Maria Buti ,&nbsp;Elena Vargas ,&nbsp;Mauro Viganò ,&nbsp;Alessandro Loglio ,&nbsp;Pietro Lampertico ,&nbsp;Roberta D’ambrosio ,&nbsp;Pinelopi Manousou","doi":"10.1016/j.cgh.2025.06.014","DOIUrl":"10.1016/j.cgh.2025.06.014","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Chronic hepatitis B (CHB) and metabolic dysfunction-associated steatotic liver disease (MASLD) commonly co-exist, with conflicting data in prevalence and disease severity. We aimed to investigate these discrepancies.</div></div><div><h3>Methods</h3><div>This multicenter study included consecutive patients with CHB from 19 European centers. A survey on standard of care for MASLD screening in CHB was circulated.</div></div><div><h3>Results</h3><div>A total of 1709 patients with CHB were included; median age, 53 years (interquartile range [IQR], 42–64); males, 60.7%; body mass index (BMI), 25.6 kg/m² (IQR, 14–63 kg/m²); and 57.3% White. MASLD prevalence (1510 consecutive patients) was 42.3%. BMI (odds ratio [OR], 1.27; 95% confidence interval [CI], 1.19–1.36), ferritin (OR, 1.00; 95% CI, 1.00–1.00) and type 2 diabetes (OR, 2.60; 95% CI, 1.12–6.02) were independently associated with MASLD. The prevalence of advanced fibrosis was 18% (255/1420) in the whole cohort, 25.4% (162/639) among patients with CHB with MASLD, and 13.7% in those without MASLD. Independent predictors of advanced fibrosis were MASLD (OR, 2.76; 95% CI, 1.50–5.05), BMI (OR, 1.08; 95% CI, 1.02–1.15), alanine transaminase (OR, 1.01; 95% CI, 1.00–1.03), lower platelets (OR, 0.99; 95% CI, 0.98–0.99), insulin treatment (OR, 13.88; 95% CI, 2.95–65.28), and long-term antivirals (OR, 4.86; 95% CI, 2.40–9.85). During follow-up (48 months), only patients without MASLD showed significant liver stiffness measurement improvement over time (<em>P</em> &lt; .001). Among patients with MASLD, Fibrosis-4 and liver stiffness measurement performed moderately at predicting advanced fibrosis (area under the receiver operating characteristic curve = 0.71 vs 0.70; <em>P</em> = .38) against histology. As standard of care, 68.4% of centers screened all patients with CHB for MASLD; 52.6% followed the same treatment indication in those with CHB and MASLD vs CHB only.</div></div><div><h3>Conclusions</h3><div>In this large European cohort, MASLD and fibrosis were highly prevalent among patients with CHB, whereas MASLD aggravated liver fibrosis. Though screening strategies remain inconsistent, ferritin levels, increased BMI, and type 2 diabetes may inform on the presence of MASLD. Biomarkers showed modest performance in predicting fibrosis.</div></div>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"24 3","pages":"Pages 701-712.e8"},"PeriodicalIF":12.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Tumor-based Universal Screening for Lynch Syndrome in Patients With Colorectal Cancer in a Large US Population","authors":"Dan Li,&nbsp;Holly A. Carwana,&nbsp;Natalia Udaltsova,&nbsp;Leslie Manace Brenman,&nbsp;Douglas A. Corley","doi":"10.1016/j.cgh.2025.07.010","DOIUrl":"10.1016/j.cgh.2025.07.010","url":null,"abstract":"","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"24 3","pages":"Pages 861-863"},"PeriodicalIF":12.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Epidemiology of Primary Biliary Cholangitis: An Updated Systematic Review and Meta-Analysis","authors":"Jarell Jie-Rae Tan ,&nbsp;Ambrose Hon-Lam Chung ,&nbsp;Jing Hong Loo ,&nbsp;Joo Wei Ethan Quek ,&nbsp;Sagar Sharma ,&nbsp;Corrine Lee Singh ,&nbsp;Roe Xin Jacqueline Yap ,&nbsp;Wei Xuan Tay ,&nbsp;Matthew K. Smith ,&nbsp;Ellina Lytvyak ,&nbsp;Andrew Mason ,&nbsp;Aldo J. Montano-Loza ,&nbsp;Yu Jun Wong","doi":"10.1016/j.cgh.2025.03.025","DOIUrl":"10.1016/j.cgh.2025.03.025","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Primary biliary cholangitis (PBC) demonstrates significant geographical variability in its epidemiology. We aim to provide an updated estimate on the global and temporal trends of the prevalence and incidence of PBC from 1976 to 2024.</div></div><div><h3>Methods</h3><div>We systematically searched three electronic databases from inception to August 20, 2024, to include all studies reporting the incidence or prevalence of PBC. The outcomes of interest were the prevalence and incidence of PBC. Subgroup analysis was performed by study type, study period, geographical region, sex, Human Development Index, method of diagnosis, and latitude. The temporal trend of PBC prevalence and incidence was analyzed using meta-regression. The study protocol was registered with PROSPERO (CRD42024595102).</div></div><div><h3>Results</h3><div>A total of 59 studies, encompassing 381 million participants and 129,455 patients with PBC across 25 countries were included. The pooled global prevalence of PBC was 18.1 cases per 100,000 people (95% confidence interval, 14.6–22.0; <em>I</em>² = 99.9%; 55 studies) among population-based studies with low risk of bias. The incidence rate of PBC was 1.8 per 100,000 person-years (95% confidence interval, 1.5–2.3; <em>I</em>² = 99.6%; 46 studies). PBC prevalence was higher in countries with higher latitude, higher Human Development Index, in America and among the female sex. Global prevalence of PBC has increased over time, with the Western Pacific region experiencing the greatest rise in PBC prevalence over time.</div></div><div><h3>Conclusions</h3><div>The rising prevalence of PBC represents a growing healthcare burden in the Western Pacific region. The association between latitude and PBC prevalence requires further studies.</div></div>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"24 3","pages":"Pages 621-632"},"PeriodicalIF":12.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wearable Technologies in Inflammatory Bowel Disease: A Scoping Review","authors":"Parna Pathak ,&nbsp;Arup Choudhury ,&nbsp;Adarsh Marikanty ,&nbsp;Anuraag Jena ,&nbsp;Shaji Sebastian ,&nbsp;Vishal Sharma","doi":"10.1016/j.cgh.2025.06.013","DOIUrl":"10.1016/j.cgh.2025.06.013","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Use of wearable technologies is increasing and may offer potential benefits in collecting actionable health data. We performed a scoping review on the use of wearable technologies in patients with inflammatory bowel disease (IBD).</div></div><div><h3>Methods</h3><div>The PubMed, Embase, and Scopus databases were searched until February 7, 2025, and original studies on the use of wearables in IBD were included. Systematic reviews, meta-analyses, comments, abstracts, and unrelated works were excluded. Data regarding study methods, participant demographics, IBD subtypes (ulcerative colitis or Crohn’s disease), and the types and brands of wearables used were extracted and presented.</div></div><div><h3>Results</h3><div>Thirty-seven studies were included. Physical activity and step counts were reported most frequently (15 and 8 studies, respectively). Sleep data (6 studies), cytokines (5 studies), heart rate variability (3 studies), and bowel sounds (1 study) were some of the other parameters analyzed. Two studies focused on virtual reality–based interventions, and 3 investigated patient attitudes toward wearable technology. The studies suggest lower physical activity in patients with IBD as compared with control subjects and in active disease as compared with remission. Changes in heart rate and heart rate variability could provide early clues to flares. Feasibility of cytokine measurements was demonstrated using sweat sensors. Sleep parameters were impacted in active IBD. Virtual reality–based interventions seemed to reduce anxiety and promote relaxation.</div></div><div><h3>Conclusions</h3><div>Wearables may be useful to improve psychosocial health of patients with IBD and contribute to holistic care. Their role in early detection of flares needs further evaluation.</div></div>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"24 3","pages":"Pages 646-666"},"PeriodicalIF":12.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144500727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLD","authors":"Yu Shi ,&nbsp;Seung Up Kim ,&nbsp;Terry Cheuk-Fung Yip ,&nbsp;Emmanuel Tsochatzis ,&nbsp;Salvatore Petta ,&nbsp;Atsushi Nakajima ,&nbsp;Hannes Hagström ,&nbsp;Elisabetta Bugianesi ,&nbsp;Wah-Kheong Chan ,&nbsp;Jérôme Boursier ,&nbsp;Boon-Bee George Goh ,&nbsp;Arun J. Sanyal ,&nbsp;Manuel Romero-Gomez ,&nbsp;José Luis Calleja ,&nbsp;Victor de Lédinghen ,&nbsp;Philip Noel Newsome ,&nbsp;Jian-Gao Fan ,&nbsp;Michelle Lai ,&nbsp;Laurent Castéra ,&nbsp;Céline Fournier ,&nbsp;Wah-Kheong Chan MD","doi":"10.1016/j.cgh.2025.06.001","DOIUrl":"10.1016/j.cgh.2025.06.001","url":null,"abstract":"<div><h3>Background</h3><div>We investigated the use of type 2 diabetes (T2D) medications, including pioglitazone, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, in individuals with T2D and metabolic dysfunction–associated steatotic liver disease (MASLD), and explored the effect of these medications on long-term risk of liver-related events (LREs) and progression of liver stiffness in a retrospective cohort study.</div></div><div><h3>Methods</h3><div>We enrolled 7867 individuals with T2D and MASLD from 16 tertiary referral centers between February 2004 and January 2023. We recorded the use of pioglitazone, GLP-1RAs, and SGLT-2 inhibitors and analyzed the effects of these antihyperglycemic medications on the risk of developing incident LREs and the progression of liver stiffness over a median of 5.1 years of follow-up.</div></div><div><h3>Results</h3><div>Pioglitazone, GLP-1RAs and SGLT-2 inhibitors were prescribed to 1238 (15.7%), 863 (11.0%), and 2386 (30.3%) individuals with T2D and MASLD, respectively. A significant increase in the utilization of GLP-1RAs and SGLT-2 inhibitors was observed from 2010–2017 to 2017–2023, with pioglitazone and SGLT-2 inhibitors being prescribed more frequently in Asian countries than in Western countries (pioglitazone: 17.9% vs 3.8%; SGLT-2 inhibitors: 34.4% vs 7.3%; <em>P</em> &lt; .001). After propensity score matching, in competing risk models, SGLT-2 inhibitor use was significantly associated with a lower risk of developing both LREs (subdistribution hazard ratio, 0.23; 95% confidence interval, 0.08–0.69, <em>P =</em> .009) and liver stiffness progression (hazard ratio, 0.54; 95% confidence interval, 0.35–0.86, <em>P =</em> .008) after adjusting for potential confounders.</div></div><div><h3>Conclusions</h3><div>SGLT-2 inhibitor use is more prevalent among Asian than Western individuals. SGLT-2 inhibitors are associated with a lower risk of LREs in individuals with T2D and MASLD.</div></div>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"24 3","pages":"Pages 723-732.e10"},"PeriodicalIF":12.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significance of Neoplasia Detection Rate in Barrett’s Esophagus: A “PEEC” Into the Data and Optimal Definitions","authors":"D.Chamil Codipilly,&nbsp;Prasad G. Iyer","doi":"10.1016/j.cgh.2025.09.033","DOIUrl":"10.1016/j.cgh.2025.09.033","url":null,"abstract":"","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"24 3","pages":"Pages 602-603"},"PeriodicalIF":12.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MASLD in Patients With Chronic Hepatitis B Virus Infection: Hiding in Plain Sight","authors":"Naim Alkhouri,&nbsp;Jean-Michel Pawlotsky","doi":"10.1016/j.cgh.2025.07.008","DOIUrl":"10.1016/j.cgh.2025.07.008","url":null,"abstract":"","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"24 3","pages":"Pages 604-605"},"PeriodicalIF":12.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blue Notes","authors":"Charles J. Kahi MD, MS, AGAF","doi":"10.1016/j.cgh.2025.12.018","DOIUrl":"10.1016/j.cgh.2025.12.018","url":null,"abstract":"","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"24 3","pages":"Pages 577-578"},"PeriodicalIF":12.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146777354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of QuickStroop for Predicting Post-TIPS Hepatic Encephalopathy","authors":"Simon J. Gairing ,&nbsp;Alena F. Ehrenbauer ,&nbsp;Sina Liedtke,&nbsp;Eva Maria Schleicher ,&nbsp;Benjamin Maasoumy ,&nbsp;Christian Labenz","doi":"10.1016/j.cgh.2025.07.016","DOIUrl":"10.1016/j.cgh.2025.07.016","url":null,"abstract":"","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"24 3","pages":"Pages 847-850"},"PeriodicalIF":12.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver Perforation From a Plastic Biliary Stent","authors":"Grace E. Kim,&nbsp;Divya Chalikonda,&nbsp;Dennis D. Chen","doi":"10.1016/j.cgh.2025.05.002","DOIUrl":"10.1016/j.cgh.2025.05.002","url":null,"abstract":"","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"24 3","pages":"Pages A21-A22"},"PeriodicalIF":12.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}